单位：[1]Division of Rheumatology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden[2]Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden[3]Department of Rheumatology, Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, 100029, China
Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune diseases. There are distinct subgroups, including antisynthetase syndrome, dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body myositis. In patients with IIM, autoantibodies are present in up to 80% of the patients. These autoantibodies are often characterized as myositis-specific autoantibodies (MSA) or myositisassociated autoantibodies (MAA). The recognition of the importance of autoantibodies, especially MSA, is increasing in recent years. In this chapter, we provide an overview of the MSAs, including some new autoantibodies of interest as they target mainly muscle-specific autoantigen, in clinical classification, the measurement of the disease activity, and a possible role in the pathogenesis in the patients with IIM.(c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
基金：
Swedish Research Council [2020e01378]; Swedish Rheumatism Association; King Gustaf V 80 Year Foundation; Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Heart and Lung Foundation; Stockholm County Council; National Natural Science Foundation of China and Beijing Municipal Science & Technology Commission
第一作者单位：[1]Division of Rheumatology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden[2]Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden[*1]Karolinska Institutet, Department of Medicine, Rheumatology Division, Center for Molecular Medicine, L8:04 Karolinska University Hospital, Solna, SE-171 76, Stockholm, Sweden.
通讯机构：[*1]Karolinska Institutet, Department of Medicine, Rheumatology Division, Center for Molecular Medicine, L8:04 Karolinska University Hospital, Solna, SE-171 76, Stockholm, Sweden.
推荐引用方式(GB/T 7714)：
Galindo-Feria Angeles S.,Wang Guochun,Lundberg Ingrid E..Autoantibodies: Pathogenic or epiphenomenon[J].BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY.2022,36(2):doi:10.1016/j.berh.2022.101767.
APA：
Galindo-Feria, Angeles S.,Wang, Guochun&Lundberg, Ingrid E..(2022).Autoantibodies: Pathogenic or epiphenomenon.BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY,36,(2)
MLA：
Galindo-Feria, Angeles S.,et al."Autoantibodies: Pathogenic or epiphenomenon".BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY 36..2(2022)
：